These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11363622)

  • 21. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delavirdine levels in women.
    Vazquez E
    Posit Aware; 1997; 8(4):14. PubMed ID: 11364481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
    Gulick RM; Hu XJ; Fiscus SA; Fletcher CV; Haubrich R; Cheng H; Acosta E; Lagakos SW; Swanstrom R; Freimuth W; Snyder S; Mills C; Fischl M; Pettinelli C; Katzenstein D
    J Infect Dis; 2002 Sep; 186(5):626-33. PubMed ID: 12195349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded access programs expanding.
    Proj Inf Perspect; 1997 Nov; (23):20-1. PubMed ID: 11365376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delavirdine approved for use in treating HIV.
    J Am Osteopath Assoc; 1997 May; 97(5):266. PubMed ID: 9195786
    [No Abstract]   [Full Text] [Related]  

  • 27. Now there are eleven, but so what?
    Gilden D
    GMHC Treat Issues; 1997; 11(4/5):1-3. PubMed ID: 11364371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delavirdine (Rescriptor).
    Res Initiat Treat Action; 2000 Mar; 6(1):20-1. PubMed ID: 11708180
    [No Abstract]   [Full Text] [Related]  

  • 32. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
    [No Abstract]   [Full Text] [Related]  

  • 33. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
    Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
    AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.
    Calmy A; Petoumenos K; Lewden C; Law M; Bocquentin F; Hesse K; Cooper D; Carr A; Bonnet F;
    HIV Med; 2007 Apr; 8(3):171-80. PubMed ID: 17461861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA notifications. NRTI Emtriva receives FDA approval.
    AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DMP 266 (Sustiva) expanded access.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):12. PubMed ID: 11364850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two new NNRTIs enter the pipeline.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):13. PubMed ID: 19048672
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.